This business sells molecular hydrogen supplements, inhalers, and other related wellness products. Meta advertising has been scaled back to almost nothing, yet the brand continues to perform with its Google Shopping campaign and a high percentage of returning customers (63% of orders). The business serves health-conscious consumers (primarily women aged 50+) and wellness clinics nationwide through its Shopify storefront.

The brand has a deep moat: US-manufactured tablets in a category dominated by Asian imports, a partnership with the Molecular Hydrogen Institute for scientific credibility, a strong reputation among healthcare practitioners and clinics, and years of accumulated organic search authority. The chargeback history across thousands of transactions is virtually spotless—zero in all of 2025 and year-to-date 2026—highlighting product quality and customer satisfaction.

A savvy, hands-on operator has their pick of growth opportunities. Restarting Meta advertising is the obvious one, but with better efficiency and discipline. The business generated $537K in revenue from Meta in 2024, but margins were severely impacted. It needs an experienced hand at the wheel.

Beyond paid advertising, a new owner could also formalize existing clinic and practitioner relationships into a structured B2B channel. Product line extensions could increase average order value and purchase frequency. Influencer and affiliate partnerships in the growing longevity and biohacking communities remain untapped. The 30,000-plus email list is active, but could use improvements.

The sellers wish to focus on a smaller set of core assets in their portfolio. The business has potential, but it needs a hands-on DTC operator with paid social expertise to grow, which the sellers are not set up to provide. They spend approximately 5 to 10 hours per week at the ownership level (with two full-time employees handling day-to-day operations), and the business needs more attention to thrive.


Key Benefits:

Turnkey Remote Operation: A 3PL manages fulfillment, and inhalers are drop-shipped.

Improving Gross Margins: A deliberate shift in focus toward tablets has pushed gross margins from approximately 51% in 2025 to the 62%–65% range in 2026.

Clinical Credibility: The business has built trust over the years and maintains a strong reputation with healthcare practitioners and clinics, demonstrating credibility that most competitors lack.

High-Profile Mentions: The business has been featured in Elephant Journal, Natural Wellness News, and several other alternative health outlets and podcasts.

Loyal Customers: There are 93 active tablet subscribers, with subscription orders averaging around $88, and 63% of all orders come from repeat buyers.

PCAOB-Audited Financials: As a subsidiary of a NASDAQ-listed company, the business has fully audited financial statements, streamlining some of the due diligence.